Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL).
This investigation evaluated variability in asthma-related quality-of-life (ARQL) outcomes among patients randomized to omalizumab or placebo. Pooled data on the Asthma Quality of Life Questionnaire (AQLQ) from two trials were used (n = 948). Variability in ARQL outcomes was determined by categorizing AQLQ score changes according to minimal clinically important difference (MCID: 0.5 points) and large clinically important difference (LCID: 1.5 points) score changes. A greater proportion of patients achieved improvement in every domain of AQLQ scores during all periods with omalizumab compared with placebo. Omalizumab-treated patients showed greater clinically important improvement in ARQL compared with patients receiving placebo.
Luskin
Allan T
AT
University of Wisconsin, Madison, Wisconsin, USA. HealthyAirways@charter.net
Kosinski
Mark
M
Bresnahan
Brian W
BW
Ashby
Mark
M
Wong
Dennis A
DA
D000293:Adolescent; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab